[New therapies against HCV].
Identifieur interne : 000110 ( France/Analysis ); précédent : 000109; suivant : 000111[New therapies against HCV].
Auteurs : Nathalie Kin [France] ; Astrid Vabret [France]Source :
- Revue francophone des laboratoires : RFL [ 1773-035X ] ; 2016.
Abstract
Human coronaviruses (HCoV) are single strand RNA viruses. To date, there are four so-called « classical » or « novel » HCoVs, characterized by a winter circulation. These coronaviruses are responsible for mild respiratory infection in general population. However, HCoVs are associated to more severe respiratory tract infection among susceptible population. Indeed, HCoVs account for 2 to 7% of hospitalizations due to a respiratory infection, particularly among children, immunocompromised or elderly people. Thereby, HCoVs are included in the panel of respiratory viruses detected in routine using molecular biology tools. These four circulating HCoVs have to be distinguished from the two emerging HCoVs: SARS-CoV and MERS-CoV. These later are associated to a more severe respiratory infection and differ from other HCoVs by their increased epidemic potential, their more important health impact, and their atypical circulation. Such as paramyxoviruses and Influenza viruses, coronaviruses have to be monitored due to their associated risk of emergence in human population from animal reservoirs.
DOI: 10.1016/S1773-035X(16)30369-0
PubMed: 32288826
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B82
- to stream PubMed, to step Curation: 000B82
- to stream PubMed, to step Checkpoint: 000B65
- to stream Ncbi, to step Merge: 003A07
- to stream Ncbi, to step Curation: 003A07
- to stream Ncbi, to step Checkpoint: 003A07
- to stream Main, to step Merge: 000F10
- to stream Main, to step Curation: 000F08
- to stream Main, to step Exploration: 000F08
- to stream France, to step Extraction: 000110
Links to Exploration step
pubmed:32288826Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[New therapies against HCV].</title><author><name sortKey="Kin, Nathalie" sort="Kin, Nathalie" uniqKey="Kin N" first="Nathalie" last="Kin">Nathalie Kin</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Recherche Risques Microbiens (EA4655), Université de Caen Normandie, Esplanade de la Paix, F-14000 Caen.</nlm:affiliation><country wicri:rule="zip">France</country><wicri:regionArea>F-14000 Caen</wicri:regionArea></affiliation></author><author><name sortKey="Vabret, Astrid" sort="Vabret, Astrid" uniqKey="Vabret A" first="Astrid" last="Vabret">Astrid Vabret</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de virologie, CHU Caen, Avenue Georges Clemenceau, F-14000 Caen.</nlm:affiliation><country wicri:rule="zip">France</country><wicri:regionArea>F-14000 Caen</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:32288826</idno><idno type="pmid">32288826</idno><idno type="doi">10.1016/S1773-035X(16)30369-0</idno><idno type="wicri:Area/PubMed/Corpus">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B82</idno><idno type="wicri:Area/PubMed/Curation">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B82</idno><idno type="wicri:Area/PubMed/Checkpoint">000B65</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B65</idno><idno type="wicri:Area/Ncbi/Merge">003A07</idno><idno type="wicri:Area/Ncbi/Curation">003A07</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A07</idno><idno type="wicri:doubleKey">1773-035X:2016:Kin N:new:therapies:against</idno><idno type="wicri:Area/Main/Merge">000F10</idno><idno type="wicri:Area/Main/Curation">000F08</idno><idno type="wicri:Area/Main/Exploration">000F08</idno><idno type="wicri:Area/France/Extraction">000110</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[New therapies against HCV].</title><author><name sortKey="Kin, Nathalie" sort="Kin, Nathalie" uniqKey="Kin N" first="Nathalie" last="Kin">Nathalie Kin</name><affiliation wicri:level="1"><nlm:affiliation>Unité de Recherche Risques Microbiens (EA4655), Université de Caen Normandie, Esplanade de la Paix, F-14000 Caen.</nlm:affiliation><country wicri:rule="zip">France</country><wicri:regionArea>F-14000 Caen</wicri:regionArea></affiliation></author><author><name sortKey="Vabret, Astrid" sort="Vabret, Astrid" uniqKey="Vabret A" first="Astrid" last="Vabret">Astrid Vabret</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de virologie, CHU Caen, Avenue Georges Clemenceau, F-14000 Caen.</nlm:affiliation><country wicri:rule="zip">France</country><wicri:regionArea>F-14000 Caen</wicri:regionArea></affiliation></author></analytic><series><title level="j">Revue francophone des laboratoires : RFL</title><idno type="ISSN">1773-035X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human coronaviruses (HCoV) are single strand RNA viruses. To date, there are four so-called « classical » or « novel » HCoVs, characterized by a winter circulation. These coronaviruses are responsible for mild respiratory infection in general population. However, HCoVs are associated to more severe respiratory tract infection among susceptible population. Indeed, HCoVs account for 2 to 7% of hospitalizations due to a respiratory infection, particularly among children, immunocompromised or elderly people. Thereby, HCoVs are included in the panel of respiratory viruses detected in routine using molecular biology tools. These four circulating HCoVs have to be distinguished from the two emerging HCoVs: SARS-CoV and MERS-CoV. These later are associated to a more severe respiratory infection and differ from other HCoVs by their increased epidemic potential, their more important health impact, and their atypical circulation. Such as paramyxoviruses and Influenza viruses, coronaviruses have to be monitored due to their associated risk of emergence in human population from animal reservoirs.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Kin, Nathalie" sort="Kin, Nathalie" uniqKey="Kin N" first="Nathalie" last="Kin">Nathalie Kin</name></noRegion><name sortKey="Vabret, Astrid" sort="Vabret, Astrid" uniqKey="Vabret A" first="Astrid" last="Vabret">Astrid Vabret</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000110 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000110 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:32288826
|texte= [New therapies against HCV].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:32288826" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |